Shares of Bionano Genomics (BNGO) experienced a dramatic plunge of 44.58% in pre-market trading on Tuesday, as investors reacted strongly to the company's announcement of a $10 million public offering. The significant drop highlights the market's immediate and negative response to the genomics company's latest financial move.

The sharp decline comes on the heels of Bionano Genomics' pricing of a public offering of 5,000,000 shares of common stock (or common stock equivalents), along with Series E and Series F warrants. The combined public offering price is set at $2.00 per share and accompanying warrants. This development has evidently spooked investors, leading to a massive sell-off in the pre-market trading session.

The market's reaction suggests that investors are deeply concerned about the potential dilution of their shares and the company's need for additional funding. While Bionano Genomics intends to use the net proceeds for working capital and general corporate purposes, the offering's impact on existing shareholders' value appears to be the primary driver of the stock's plummet. As the trading day progresses, it remains to be seen how this news will continue to affect Bionano Genomics' stock price and whether the company will provide additional context or reassurances to mitigate investor concerns.